drugset
drugset / Trial / NCT05527301

HEM1036 Phase 2 Study in Low Anterior Resection Syndrome

NCT05527301 ↗

Phase 2 Unknown 67 enrolled HEM Pharma Inc. Premier Research · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

Double-blind, randomized, placebo controlled phase 2 study to explore the efficacy and safety of HEM1036 in the treatment of subjects with LARS

Timeline

Start
2024-01-01
Primary completion
2026-01-01
Completion
2026-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lactobacillus Fermentum Other / unclassified 1e+10 unknown Oral

Indications

No indication recorded.